Home > Boards > US Listed > Biotechs > Lexicon Genetics (LXRX)

DILUTION > SHELF PLACEMENT > SEC

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 655
Posts 43,598
Boards Moderated 12
Alias Born 12/12/04
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2020 7:23:07 AM
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Sci... GlobeNewswire Inc. - 11/16/2020 10:01:39 PM
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference GlobeNewswire Inc. - 11/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/30/2020 5:11:39 PM
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update GlobeNewswire Inc. - 10/29/2020 6:00:10 AM
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020 GlobeNewswire Inc. - 10/27/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/29/2020 7:14:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2020 7:13:15 AM
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness GlobeNewswire Inc. - 9/23/2020 6:43:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:12:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/8/2020 5:03:21 PM
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics GlobeNewswire Inc. - 9/8/2020 4:05:10 PM
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients... GlobeNewswire Inc. - 9/4/2020 8:00:10 AM
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtu... GlobeNewswire Inc. - 9/3/2020 6:00:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:00:51 AM
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire (US) - 8/3/2020 7:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:19:01 AM
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program GlobeNewswire Inc. - 7/30/2020 7:15:10 AM
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO GlobeNewswire Inc. - 7/30/2020 7:10:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:05:27 AM
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 7/29/2020 5:08:32 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/29/2020 4:57:55 PM
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020 GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes GlobeNewswire Inc. - 7/21/2020 7:00:10 AM
crudeoil24 Member Level  Tuesday, 11/17/20 07:22:41 AM
Re: None
Post # of 640 
DILUTION > SHELF PLACEMENT > SEC 424B5 >LXRX has entered into an Open Market Sale AgreementSM (the “sales agreement”) with Jefferies LLC (“Jefferies”) relating to the shares of our common stock, par value $0.001 per share (“common stock”), offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell our common stock having an aggregate sales price of up to $50,000,000 from time to time through Jefferies acting as our sales agent.
Our common stock trades on the Nasdaq under the symbol “LXRX.” On October 29, 2020, the last reported sale price of our common stock on the Nasdaq was $1.16 per share.
Sales of common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to Jefferies for sales of common stock sold pursuant to the sales agreement will be at an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. The net proceeds from any sales under this prospectus supplement will be used as described under “Use of Proceeds” in this prospectus supplement. In connection with the sale of the common stock on our behalf, the Jefferies will be deemed to be “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. See “Plan of Distribution” on page S-7 of this prospectus supplement for additional information concerning the compensation to be paid to Jefferies.


New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences